Eli

ZOE Announces $53M Total Raise from Investors Including Fund Backed by Top Scientists, and Two-Time Super Bowl Champion, Eli Manning

Tuesday, May 4, 2021 - 1:45pm

Funds to Meet Accelerating Demand for First-of-its-Kind At-Home Test Kit and Program That Brings Cutting-Edge Research to Your Dinner Plate

Key Points: 
  • ZOE decodes each customer\'s unique biological responses to food, and guides them on how to eat to maximize long-term health.
  • This round of financing is led by Ahren Innovation Capital ("Ahren"), whose Science Partners include two Nobel laureates.
  • "\nAdditional participants in this financing include two-time Super Bowl Champion and MVP, Eli Manning, two-time Super Bowl Champion and award-winning sportscaster, Ositadimma "Osi" Umenyiora, Accomplice (the fund behind AngelList, DraftKings, PillPack, and WHOOP), THVC and Daphni.\nUmenyiora said, "I\'m really excited to invest in ZOE.
  • "\nThe funds from the investment will be used to speed up the rollout of the ZOE program.

BBQGuys Extends Relationships With NFL Legends Archie and Eli Manning as Brand Ambassadors to Launch First National Marketing Campaign

Tuesday, March 30, 2021 - 1:00pm

BATON ROUGE, La., March 30, 2021 /PRNewswire/ --BBQGuys, the leading e-commerce retailer for grilling and outdoor living, announced today that NFL legends and BBQGuys investors, Archie and Eli Manning, will serve as the company's first-ever brand ambassadors.

Key Points: 
  • BATON ROUGE, La., March 30, 2021 /PRNewswire/ --BBQGuys, the leading e-commerce retailer for grilling and outdoor living, announced today that NFL legends and BBQGuys investors, Archie and Eli Manning, will serve as the company's first-ever brand ambassadors.
  • As part of the agreement, Archie and Eli will be featured in BBQGuys' national advertising campaign debut.
  • "Barbequesare aboutso much more thanjustgreat food; they build friendships, connect families and forgecommunity bonds that last a lifetime," said Jason Stutes, Chief Digital Officer, BBQGuys.
  • "The Manning family is proud to partner with BBQGuys to help people create their memories and moments that last a lifetime."

Insperity Appoints Independent Director to Board

Wednesday, December 16, 2020 - 9:30pm

Insperity, Inc. (NYSE: NSP), a leading provider of human resources and business performance solutions for Americas best businesses, today announced that its board of directors has appointed Dr. Eli Jones as an independent director.

Key Points: 
  • Insperity, Inc. (NYSE: NSP), a leading provider of human resources and business performance solutions for Americas best businesses, today announced that its board of directors has appointed Dr. Eli Jones as an independent director.
  • We are very pleased to welcome Eli back to the board, said Paul J. Sarvadi, chairman and chief executive officer.
  • Dr. Jones has been appointed as a Class III director with a term expiring at our annual meeting of the stockholders in 2022.
  • Dr. Jones was also a director of Insperity from 2004 through June 2016.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY

Tuesday, October 27, 2020 - 12:00am

NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company (Eli Lilly or the Company) (NYSE:LLY).

Key Points: 
  • NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company (Eli Lilly or the Company) (NYSE:LLY).
  • Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext.
  • On this news, Eli Lillys stock price fell $4.41 per share, or 2.85%, to close at $150.08 per share on October 13, 2020.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm

Wednesday, October 21, 2020 - 12:00am

NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders.

Key Points: 
  • NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders.
  • Our investigation concerns whether Eli Lilly has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On August 2020, Eli Lilly began a clinical trial to test whether adding the Companys antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, the Company's stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.

The Law Offices of Frank R. Cruz Continues Its Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Tuesday, October 20, 2020 - 6:00pm

The Law Offices of Frank R. Cruz continues its investigation of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz continues its investigation of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • In August 2020, the Company began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, Eli Lillys stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Tuesday, October 20, 2020 - 4:00pm

Law Offices of Howard G. Smith continues its investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith continues its investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of federal securities laws.
  • In August 2020, the Company began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, Eli Lillys stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm

Friday, October 16, 2020 - 1:00am

NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders.

Key Points: 
  • NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders.
  • Our investigation concerns whether Eli Lilly has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On August 2020, Eli Lilly began a clinical trial to test whether adding the Companys antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, the Company's stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.

The Law Offices of Frank R. Cruz Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Wednesday, October 14, 2020 - 9:58pm

The Law Offices of Frank R. Cruz announces an investigation of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • In August 2020, the Company began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, Eli Lillys stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Wednesday, October 14, 2020 - 9:00pm

Law Offices of Howard G. Smith announces an investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Eli Lilly and Company (Eli Lilly or the Company) (NYSE: LLY ) investors concerning the Companys possible violations of federal securities laws.
  • In August 2020, the Company began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with COVID-19.
  • On this news, Eli Lillys stock price fell $4.41, or 2.8%, to close at $150.08 per share on October 13, 2020.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.